SIRT6 Antibody (YA7392)

SIRT6 is a nuclear NAD⁺-dependent sirtuin that functions as a deacetylase, deacylase, and mono-ADP-ribosyltransferase, thereby maintaining chromatin integrity, DNA repair capacity, telomere stability, and metabolic homeostasis^[1][2]. Mechanistically, SIRT6 regulates multiple signaling and transcriptional programs involved in aging, cellular stress responses, glucose and lipid metabolism, inflammation, and genome maintenance, placing it at the intersection of epigenetic regulation and cellular adaptation^[2][5][3]. Through its effects on DNA damage repair, chromosome maintenance, and metabolic control, SIRT6 contributes to the preservation of cellular function and resistance to age-associated dysfunction^[5][3]. In disease contexts, altered SIRT6 activity has been linked to cancer, cardiovascular disease, diabetes, and neurodegenerative disorders, while experimental studies demonstrate that SIRT6 deficiency induces mitochondrial dysfunction, oxidative stress, and broad transcriptional changes associated with brain aging and neurodegeneration^[2][4]. Compared with related sirtuin isoforms, SIRT6 is distinguished by its predominant chromatin-associated functions and its combined deacetylase, deacylase, and mono-ADP-ribosyltransferase activities that directly couple NAD⁺ sensing to epigenetic and genome-stability pathways^[1][5]. For experimental applications, increasing attention has focused on small-molecule SIRT6 modulators, including both activators and inhibitors, which provide useful tools for mechanistic studies and evaluation of SIRT6-dependent pathways in aging, metabolism, cancer, and neurodegenerative disease models^[2][6].